mitazalimab + mFOLFIRINOX

Mitazalimab + mFOLFIRINOX is a combination regimen used in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). **Mitazalimab** is a human monoclonal antibody and agonist of CD40, activating immune cells to stimulate antitumor responses. **mFOLFIRINOX** (modified FOLFIRINOX) is a combination chemotherapy protocol that includes folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin; these agents act as cytotoxic drugs that kill rapidly dividing cancer cells. The regimen is administered intravenously, typically following a schedule where mitazalimab is given on specific days (with priming before mFOLFIRINOX and booster doses after), and mFOLFIRINOX is given in regular multi-drug cycles. This combination has shown improved objective response rate and overall survival relative to standard care in clinical trials and is under development as a front-line therapy for metastatic pancreatic cancer[1][3][5].

Other names

mitazalimab + modified FOLFIRINOXmitazalimab + folinic acid + fluorouracil + irinotecan + oxaliplatin